- RedHill Biopharma Ltd (NASDAQ: RDHL) has announced agreements with Cosmo Pharmaceuticals NV to manufacture RedHill's largest selling product in the U.S., Movantik, and RHB-204, currently in a Phase 3 U.S. study as a stand-alone, first-line orally-administered treatment for pulmonary nontuberculous mycobacteria (NTM) disease.
- Movantik is a prescribed oral peripherally acting mu-opioid receptor antagonist in the U.S. specifically to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
- RHB-204 is an investigational proprietary, a fixed-dose oral capsule containing a combination of clarithromycin, rifabutin, and clofazimine.
- Last month, RedHill entered into a manufacturing agreement with Cosmo Pharmaceuticals to expand its manufacturing capacity for opaganib (Yeliva, ABC294640), currently in a Phase 2a study in advanced cholangiocarcinoma and a Phase 2 study in prostate cancer. Opaganib is also being evaluated as a treatment for COVID-19 pneumonia in a global Phase 2/3 study and has demonstrated positive safety and efficacy signals.
- Price Action: RDHL stock dropped 4.2% at $10.38 in market trading hours on last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in